Navigation Links
Technique May Let More Women Use Tamoxifen
Date:2/23/2009

30% of breast cancers currently don't respond to this type of estrogen-linked drug

MONDAY, Feb. 23 (HealthDay News) -- Researchers have found a way to "switch on" estrogen sensitivity in breast tumor cells, thereby making them vulnerable to the breast cancer drug tamoxifen.

If successful, the technique might someday allow breast cancer patients who don't respond to tamoxifen to benefit from the drug.

"We're excited by the results," said study author Caroline Ford, a member of the department of cell and experimental pathology at Lund University in Malmo, Sweden. "This has implications for the 30 percent of breast cancer patients who are estrogen-receptor negative who currently have a poor prognosis."

Not only might these tumors become amenable to tamoxifen, but they may also respond to other "endocrine" treatments such as aromatase inhibitors, which also interfere with estrogen production in the body.

"We are currently investigating this," Ford said.

The findings may also provide alternatives for the group of women who start out estrogen receptor-positive but later become negative and for whom treatments stop working.

The findings are published in this week's issue of the Proceedings of the National Academy of Sciences.

As Ford noted, a large minority of patients have breast cancer tumors that do not express estrogen receptors. Not only does this make them unresponsive to a variety of treatments now available for estrogen receptor-positive malignancies, but it indicates a more aggressive cancer in general.

Tamoxifen, which has been a gold standard of breast cancer treatment for decades, works by binding to the estrogen receptor. If there is no receptor, however, tamoxifen becomes useless.

Any means of allowing the three out of 10 women whose cancers don't respond to tamoxifen and other endrocrine therapies would be a big advance, experts say.

"[Research] groups have been looking to restore positivity, to open the door to treatment with tamoxifen and aromatase inhibitors," said Dr. Minetta Liu, a translational researcher and breast oncologist at Georgetown University's Lombardi Comprehensive Cancer Center in Washington, D.C. The Swedish team now "have a molecule suggested that may, in fact, succeed. The findings are very exciting," he said.

So far, however, these promising results have only been seen in the lab and would need to be confirmed in animal models. If those experiments are successful, human trials would come next.

So how does the new technique work? In prior trials, researchers had noticed an association between cells that didn't express the estrogen receptor and a loss of expression of Wnt-5a, a key signaling protein.

This led to a theory that Wnt-5a might regulate estrogen receptor levels and, in fact, this seemed to be the case. Re-establishing Wnt-5a signaling resulted in higher estrogen receptor levels in estrogen receptor-negative cells.

But, the authors pointed out, Wnt-5a is probably too large a molecule to be administered directly to patients.

But Foxy-5, a smaller molecule and a Wnt-5a analog (look-alike) developed in the laboratory, did the same job as effectively, the team said.

Ford, along with a co-author of the paper, has filed a patent for the effects of the Foxy-5 peptide on estrogen receptors.

In related research, another study in the same issue of PNAS found that a protein called lipocalin 2 can indicate how invasive a breast cancer is likely to be. Better yet, levels of the protein can be measured in urine.

Apparently, lipocalin 2 decreases estrogen receptor levels, which indicates the presence of more aggressive cancer, according to researchers at Children's Hospital Boston.

Testing for the protein could help doctors and patients decide when more aggressive treatments might be appropriate.

More information

There's more on estrogen receptors at the U.S. National Cancer Institute.



SOURCES: Caroline Ford, Ph.D., department of cell and experimental pathology, Lund University, Malmo, Sweden; Minetta Liu, M.D., translational researcher/breast oncologist, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C.; Feb. 23-27, 2009, Proceedings of the National Academy of Sciences


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Eye-staining technique offers early detection for dry eye syndrome
2. New technique detects specific chromosomal damage, may indicate lung cancer risk
3. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
4. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
5. Accuray Receives FDA Clearance for New Dose Calculation Technique for Body Radiosurgery
6. Radiation therapy technique reduces length of prostate cancer treatment
7. Radiation therapy technique reduces length of prostate cancer treatment
8. IVF technique enables pregnancy without multiple births, Stanford researchers find
9. UT Southwestern investigating hypothermic technique in treating pediatric head injuries
10. UCLA doctor develops new technique to treat varicose veins
11. New technique improves purity of medicines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Technique May Let More Women Use Tamoxifen
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies perfectly ... in the company’s esteemed VISION House demonstration project series. Manifesting the concept of right-sized ... resources they need to live affordably and abundantly without unduly taxing the resources of ...
(Date:4/21/2017)... ... 21, 2017 , ... The VIA Agency , a ... Theravent, Inc. , the makers of a revolutionary new device clinically proven ... now working to expand distribution in anticipation of a national launch. VIA will ...
(Date:4/21/2017)... Arvada, CO (PRWEB) , ... April 21, 2017 ... ... health and performance system, has partnered with O2X , an active lifestyle ... are focused on improving the health of firefighters, police offers, first responders, military ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness ... to overcome their mental health struggles. The Alive team uses advanced behavioral sciences ... approach in dealing with a mental health struggle is based on 10 modalities ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... anticipated Regional Primary Care Spring Symposium on April 1, 2017 in Santa Rosa. ... offering physicians and healthcare providers an opportunity to learn about cutting edge treatments, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group leased ... is developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company ... life-threatening diseases that have been underserved by scientific ... therapies for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... 18, 2017 Viverae ® , a leader ... integration of IBM ® Watson Campaign Automation, implementing ... communications for a personalized experience. Through digital engagement, the ... health in real time. The enhanced experience drives engagement ... members, wherever they are in their journey to health. ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
Breaking Medicine Technology: